{"access":{"can_view":true,"can_edit":false,"can_remove":false,"can_add":false,"can_publish":false,"can_get_doi":false,"can_share":true,"can_move":true,"can_move_outside":true,"can_transfer":true,"can_download":true,"limited_run":false,"limited_private_links":false,"limited_blind_links":false,"is_locked":false},"authors":[{"name":"Alexander Domnich","affiliation":"IRCCS Ospedale Policlinico San Martino","affiliation_url":"","username":"alexander-domnich","link":"","image":{"source":"/img/avatars/011.png","placeholder":"/img/avatars/011.png","webp_source":""},"note":"","is_verified_user":true},{"name":"Giovanna Elisa Calabrò","affiliation":"Section of Hygiene, Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, Rome, Italy","affiliation_url":null,"username":"n4vle1z1q1y4rle1","link":null,"image":{"source":"/img/avatars/014.png","placeholder":"/img/avatars/014.png","webp_source":""},"note":"","is_verified_user":true}],"before_start":"","book_chapter":null,"can_accept_authorship":false,"can_be_copied":true,"can_claim_authorship":false,"can_manage_keywords":true,"can_remove_fork":false,"can_sign":false,"child_steps":{},"cited_protocols":[],"collection_items":[],"created_on":1700555782,"creator":{"name":"Alexander Domnich","affiliation":"IRCCS Ospedale Policlinico San Martino","affiliation_url":"","username":"alexander-domnich","link":"","image":{"source":"/img/avatars/011.png","placeholder":"/img/avatars/011.png","webp_source":""},"badges":[{"id":2,"name":"Author","image":{"source":"/img/badges/bronze.svg","placeholder":"/img/badges/bronze.svg"}}],"affiliations":[{"affiliation":"IRCCS Ospedale Policlinico San Martino","url":"","is_default":true}]},"cross_cloud_origin":null,"description":"{\"blocks\":[{\"key\":\"6q405\",\"text\":\"Globally, respiratory syncytial virus (RSV) is a leading cause of respiratory infections and is responsible for a significant socioeconomic burden in all age groups, including adults. To date, no review systematically appraised the burden of RSV in Italian adults. Understanding country-specific burden of disease is a key driver for policy decisions on the introduction of new vaccines. In fact, two vaccines have been recently authorized to prevent lower respiratory tract disease caused by RSV in adults. In this protocol for a systematic review, we aim to collect and analyze data on the clinical burden of RSV in Italian adults with the goal of informing and supporting National and local decision makers on the planification and implementation of future vaccination strategies.\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}}],\"entityMap\":{}}","disclaimer":"","document":"","documents":[{"id":421953,"guid":"","type_id":0,"filename":"","key":"","color":"","height":0,"width":0,"is_document":null,"original_file_id":null,"thumb_url":"https://www.protocols.io/img/extensions/pdf.png","size":200439,"is_private":0,"is_new":0,"ofn":"Prot_SRMA_RSV_Ita_v13112013.pdf","url":"https://content.protocols.io/files/n6cbcahfp.pdf","bucket_name":null,"s3_webp_url":"","file_id":421953}],"doi":"dx.doi.org/10.17504/protocols.io.5qpvo32odv4o/v1","doi_status":1,"ethics_statement":null,"fork_id":null,"fork_info":null,"forks":[],"funders":[],"groups":[],"guid":"C88F4E4ABB9946678171704CB70ABAE1","guidelines":"","has_references":true,"has_step_reagents":false,"has_versions":false,"id":91240,"image":{"source":"https://www.protocols.io/img/default_protocol.png","webp_source":null,"placeholder":"https://www.protocols.io/img/default_protocol.png","webp_placeholder":null},"image_attribution":"","in_trash":false,"is_bookmarked":false,"is_contact_suspended":false,"is_content_confidential":false,"is_content_warning":false,"is_doi_reserved":true,"is_in_pending_publishing":false,"is_in_transfer":false,"is_owner":true,"is_research":true,"is_retracted":false,"is_shared_directly":false,"is_subprotocol":null,"is_unlisted":false,"item_id":1189881,"journal":null,"journals":[],"keywords":"","last_modified":1700562406,"link":"","location":null,"manuscript_citation":"","materials":[],"materials_text":"","ownership_history":null,"parent_collections":[],"parent_protocols":[],"peer_reviewed":false,"protocol_references":"{\"blocks\":[{\"key\":\"arpco\",\"text\":\"Barker TH, Migliavaca CB, Stein C, Colpani V, Falavigna M, Aromataris E,\\nMunn Z. Conducting proportional meta-analysis in different types of systematic\\nreviews: a guide for synthesisers of evidence. BMC Med Res Methodol.\\n2021;21(1):189. doi: 10.1186/s12874-021-01381-z.\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"7uvfg\",\"text\":\"Bergeri I, Whelan MG, Ware H, Subissi L, Nardone A, Lewis HC, Li Z, Ma X,\\nValenciano M, Cheng B, Al Ariqi L, Rashidian A, Okeibunor J, Azim T, Wijesinghe\\nP, Le LV, Vaughan A, Pebody R, Vicari A, Yan T, Yanes-Lane M, Cao C, Clifton\\nDA, Cheng MP, Papenburg J, Buckeridge D, Bobrovitz N, Arora RK, Van Kerkhove\\nMD; Unity Studies Collaborator Group. Global SARS-CoV-2 seroprevalence from\\nJanuary 2020 to April 2022: A systematic review and meta-analysis of\\nstandardized population-based studies. PLoS\\nMed. 2022;19(11):e1004107. doi: 10.1371/journal.pmed.1004107.\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"9i1tp\",\"text\":\"Boccalini S, Bonito B, Salvati C, Del Riccio M, Stancanelli E, Bruschi M, Ionita G, Iamarino J,\\nBentivegna D, Buscemi P, Ciardi G, Cosma C, Stacchini L, Conticello C, Bega M,\\nSchirripa A, Paoli S, Bertizzolo L, Parisi S, Trippi F, Bonanni P, Bechini A.\\nHuman respiratory syncytial virus epidemiological burden in pediatric\\noutpatients in Italy: A systematic review. Vaccines (Basel).\\n2023;11(9):1484. doi: 10.3390/vaccines11091484.\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"6s0hj\",\"text\":\"Cai W, Tolksdorf K, Hirve S, Schuler E, Zhang W, Haas W, Buda S. Evaluation\\nof using ICD-10 code data for respiratory syncytial virus surveillance.\\nInfluenza Other Respir Viruses. 2020;14(6):630-637. doi: 10.1111/irv.12665.\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"35cki\",\"text\":\"Centers for Disease Control and Prevention (CDC). Healthcare providers:\\nRSV vaccination for adults 60 years of age and over. Available at:\\nhttps://www.cdc.gov/vaccines/vpd/rsv/hcp/older-adults.html#:~:text=CDC%20recommends%20that%20adults%2060,RSV%20vaccination%20will%20be%20beneficial.\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"8unhp\",\"text\":\"Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions,\\nVersion 5.1.0, updated March 2011. Meta-regression. Available at:\\nhttps://handbook-5-1.cochrane.org/chapter_9/9_6_4_meta_regression.htm#:~:text=Meta%2Dregression%20should%20generally%20not,one%20or%20more%20explanatory%20variables.\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"cd75s\",\"text\":\"Du Y, Yan R, Wu X, Zhang X, Chen C, Jiang D, Yang M, Cao K, Chen M, You\\nY, Zhou W, Chen D, Xu G, Yang S. Global burden and trends of respiratory\\nsyncytial virus infection across different age groups from 1990 to 2019: A\\nsystematic analysis of the Global Burden of Disease 2019 Study. Int J Infect\\nDis. 2023;135:70-76. doi: 10.1016/j.ijid.2023.08.008.\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"psj9\",\"text\":\"Gomez GB, Mahé C, Chaves SS. Uncertain effects of the pandemic on\\nrespiratory viruses. Science. 2021;372(6546):1043-1044. doi:\\n10.1126/science.abh3986.\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"fjfo3\",\"text\":\"Haddaway NR, Collins AM, Coughlin D, Kirk S. The role of Google Scholar\\nin evidence reviews and its applicability to grey literature searching. PLoS\\nOne. 2015;10(9):e0138237. doi: 10.1371/journal.pone.0138237.\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"2n4ht\",\"text\":\"Hamid S, Winn A, Parikh R, Jones JM, McMorrow M, Prill MM, Silk BJ,\\nScobie HM, Hall AJ. Seasonality of respiratory syncytial virus - United States,\\n2017-2023. MMWR Morb Mortal Wkly Rep. 2023;72(14):355-361. doi:\\n10.15585/mmwr.mm7214a1.\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"fhfnq\",\"text\":\"Haynes AK, Manangan AP, Iwane MK, Sturm-Ramirez K, Homaira N, Brooks WA,\\nLuby S, Rahman M, Klena JD, Zhang Y, Yu H, Zhan F, Dueger E, Mansour AM, Azazzy\\nN, McCracken JP, Bryan JP, Lopez MR, Burton DC, Bigogo G, Breiman RF, Feikin\\nDR, Njenga K, Montgomery J, Cohen AL, Moyes J, Pretorius M, Cohen C, Venter M,\\nChittaganpitch M, Thamthitiwat S, Sawatwong P, Baggett HC, Luber G, Gerber SI.\\nRespiratory syncytial virus circulation in seven countries with Global Disease\\nDetection Regional Centers. J Infect Dis. 2013;208 Suppl 3:S246-54. doi:\\n10.1093/infdis/jit515.\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"bk6cg\",\"text\":\"Kotton CN. More protection against respiratory viral infection:\\nRespiratory syncytial virus vaccines for adults aged 60 years and older. Ann\\nIntern Med. 2023 Oct;176(10):1419-1421. doi: 10.7326/M23-2196.\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"4lseo\",\"text\":\"Levine MM, Levine OS. Influence of disease burden, public perception, and\\nother factors on new vaccine development, implementation, and continued use.\\nLancet. 1997;350(9088):1386-92. doi: 10.1016/S0140-6736(97)03253-4.\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"97rut\",\"text\":\"Li Y, Kulkarni D, Begier E, Wahi-Singh P, Wahi-Singh B, Gessner B, Nair\\nH. Adjusting for case under-ascertainment in estimating RSV hospitalisation\\nburden of older adults in high-income countries: a systematic review and\\nmodelling study. Infect Dis Ther. 2023;12(4):1137-1149. doi: 10.1007/s40121-023-00792-3.\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"7754c\",\"text\":\"Maggi S, Veronese N, Burgio M, Cammarata G, Ciuppa ME, Ciriminna S, Di\\nGennaro F, Smith L, Trott M, Dominguez LJ, Giammanco GM, De Grazia S,\\nCostantino C, Vitale F, Barbagallo M. Rate of hospitalizations and mortality of\\nrespiratory syncytial virus infection compared to influenza in older people: A systematic\\nreview and meta-analysis. Vaccines (Basel). 2022 Dec 7;10(12):2092. doi:\\n10.3390/vaccines10122092.\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"3rnve\",\"text\":\"McLaughlin JM, Khan F, Begier E, Swerdlow DL, Jodar L, Falsey AR. Rates\\nof Medically Attended RSV Among US Adults: A Systematic Review and\\nMeta-analysis. Open Forum Infect Dis. 2022 Jun 17;9(7):ofac300. doi:\\n10.1093/ofid/ofac300.\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"7j0r7\",\"text\":\"Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance\\nfor systematic reviews of observational epidemiological studies reporting\\nprevalence and cumulative incidence data. Int J Evid Based Healthc.\\n2015;13(3):147-53. doi: 10.1097/XEB.0000000000000054.\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"93rcc\",\"text\":\"Munn Z, Stern C, Aromataris E, Lockwood C, Jordan Z. What kind of\\nsystematic review should I conduct? A proposed typology and guidance for\\nsystematic reviewers in the medical and health sciences. BMC Med Res Methodol.\\n2018;18(1):5. doi: 10.1186/s12874-017-0468-4.\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"7hqdl\",\"text\":\"Osei-Yeboah R, Spreeuwenberg P, Del Riccio M, Fischer TK, Egeskov-Cavling\\nAM, Bøås H, van Boven M, Wang X, Lehtonen T, Bangert M, Campbell H, Paget J;\\nRESCEU investigators. Estimation of the number of RSV-associated\\nhospitalisations in adults in the European Union. J Infect Dis. 2023 May\\n29:jiad189. doi: 10.1093/infdis/jiad189.\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"7scm0\",\"text\":\"Nguyen-Van-Tam JS, O'Leary M, Martin ET, Heijnen E, Callendret B,\\nFleischhackl R, Comeaux C, Tran TMP, Weber K. Burden of respiratory syncytial\\nvirus infection in older and high-risk adults: a systematic review and\\nmeta-analysis of the evidence from developed countries. Eur Respir Rev.\\n2022;31(166):220105. doi: 10.1183/16000617.0105-2022.\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"644cr\",\"text\":\"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD,\\nShamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM,\\nHróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness\\nLA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA\\n2020 statement: an updated guideline for reporting systematic reviews. BMJ.\\n2021;372:n71. doi: 10.1136/bmj.n71. \",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"1oepp\",\"text\":\"Pisesky A, Benchimol EI, Wong CA, Hui C, Crowe M, Belair MA, Pojsupap S,\\nKarnauchow T, O'Hearn K, Yasseen AS 3rd, McNally JD. Incidence of hospitalization\\nfor respiratory syncytial virus infection amongst children in Ontario, Canada:\\nA population-based study using validated health administrative data. PLoS One.\\n2016;11(3):e0150416. doi: 10.1371/journal.pone.0150416.\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"4ak4o\",\"text\":\"Rafferty E, Paulden M, Buchan SA, Robinson JL, Bettinger JA, Kumar M,\\nSvenson LW, MacDonald SE; Canadian Immunization Research Network (CIRN)\\ninvestigators. Evaluating the individual healthcare costs and burden of disease\\nassociated with RSV across age groups. Pharmacoeconomics. 2022;40(6):633-645.\\ndoi: 10.1007/s40273-022-01142-w.\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"61ulj\",\"text\":\"Rozenbaum MH, Begier E, Kurosky SK,\\nWhelan J, Bem D, Pouwels KB, Postma M, Bont L. Incidence of respiratory syncytial\\nvirus infection in older adults: Limitations of current data. Infect Dis Ther.\\n2023;12(6):1487-1504. doi: 10.1007/s40121-023-00802-4.\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"1e6fg\",\"text\":\"Shi T, Denouel A, Tietjen AK, Campbell I, Moran E, Li X, Campbell H,\\nDemont C, Nyawanda BO, Chu HY, Stoszek SK, Krishnan A, Openshaw P, Falsey AR,\\nNair H; RESCEU Investigators. Global disease burden estimates of respiratory\\nsyncytial virus-associated acute respiratory infection in older adults in 2015:\\nA systematic review and meta-analysis. J Infect Dis. 2020;222(Suppl\\n7):S577-S583. doi: 10.1093/infdis/jiz059.\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"17m2f\",\"text\":\"Shi T, Vennard S, Jasiewicz F, Brogden R, Nair H; RESCEU Investigators.\\nDisease burden estimates of respiratory syncytial virus related acute respiratory\\ninfections in adults with comorbidity: A systematic review and meta-analysis. J\\nInfect Dis. 2022;226(Suppl 1):S17-S21. doi: 10.1093/infdis/jiab040.\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"cr13g\",\"text\":\"Staadegaard L, Caini S, Wangchuk S, Thapa B, de Almeida WAF, de Carvalho\\nFC, Njouom R, Fasce RA, Bustos P, Kyncl J, Novakova L, Caicedo AB, de Mora\\nColoma DJ, Meijer A, Hooiveld M, Huang S, Wood T, Guiomar R, Rodrigues AP,\\nDanilenko D, Stolyarov K, Lee VJM, Ang LW, Cohen C, Moyes J, Larrauri A,\\nDelgado-Sanz C, Le MQ, Hoang PVM, Demont C, Bangert M, van Summeren J, Dückers\\nM, Paget J. The global epidemiology of RSV in community and hospitalized care: Findings\\nfrom 15 countries. Open Forum Infect Dis. 2021;8(7):ofab159. doi: 10.1093/ofid/ofab159.\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"ne9l\",\"text\":\"Tin Tin Htar M, Yerramalla MS, Moïsi JC, Swerdlow DL. The burden of\\nrespiratory syncytial virus in adults: a systematic review and meta-analysis.\\nEpidemiol Infect. 2020 Feb 13;148:e48. doi: 10.1017/S0950268820000400.\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"d2mhj\",\"text\":\"United Kingdom Department of Health \\u0026 Social Care. Respiratory syncytial virus\\n(RSV) immunisation programme for infants and older adults: JCVI full statement,\\n11 September 2023. Available at:\\nhttps://www.gov.uk/government/publications/rsv-immunisation-programme-jcvi-advice-7-june-2023/respiratory-syncytial-virus-rsv-immunisation-programme-for-infants-and-older-adults-jcvi-full-statement-11-september-2023.\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"5aeu8\",\"text\":\"\\n\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}}],\"entityMap\":{}}","public":true,"public_fork_note":"","published_on":1700562406,"references":[],"related_equipments":[],"related_materials":[],"reserved_doi":"10.17504/protocols.io.5qpvo32odv4o/v1","retraction_reason":null,"samples":{},"shared_access_id":0,"show_comparison":false,"sign_info":null,"space_access":{"can_view":false,"can_edit":false,"can_remove":false,"can_add":false,"can_publish":true,"can_get_doi":true,"can_share":false,"can_move":false,"can_move_outside":false,"can_transfer":false,"can_download":false,"limited_run":false,"limited_private_links":false,"limited_blind_links":false,"is_locked":false},"state_version_id":54,"stats":{"is_voted":false,"number_of_views":0,"number_of_steps":2,"number_of_bookmarks":0,"number_of_comments":0,"number_of_bookmarked_comments":0,"number_of_steps_comments":0,"number_of_protocol_comments":0,"number_of_exports":0,"number_of_runs":0,"number_of_votes":0,"number_of_reagents":0,"number_of_equipments":0,"number_of_collections":0,"number_of_forks":{"private":0,"public":0},"number_of_accessible_forks":0},"status":{"id":1,"info":"We use this protocol and it's working"},"steps":[{"id":1855436,"guid":"954F72F5583E4884A0A285AC10145C2A","previous_id":0,"previous_guid":null,"section":"\u003cp\u003eIntroduction\u003c/p\u003e","section_color":"#A492FF","section_duration":0,"is_substep":false,"step":"{\"blocks\":[{\"key\":\"1ondj\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"659s7\",\"text\":\"Together with seasonal influenza, respiratory syncytial virus (RSV) is a\\nleading cause of respiratory infections and is responsible for a significant\\nsocioeconomic burden in all age groups, especially at the extremes of age [McLaughlin,\\n2022; Rafferty, 2022]. Indeed, a recent modelling study [Osei-Yeboah, 2023] has\\nestimated that on average, a total of 158,229 RSV-associated hospitalizations among\\nEuropean adults occur annually and 92% of these concern older adults aged ≥ 65\\nyears. Contrary to young children, in the last 20 years mortality attributable\\nto RSV increased in both working-age and older adults [Du, 2023].\",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"5usg3\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"9l54d\",\"text\":\"Several systematic reviews [Shi, 2020; Tin Tin Htar, 2020; Nguyen-Van-Tam,\\n2022; Shi, 2022; Maggi, 2022; Li, 2023] have investigated global epidemiology\\nand burden of RSV in (older) adults. These reviews have confirmed significant\\nRSV attack rates, hospitalization, mortality and case-fatality rates [Shi,\\n2020; Tin Tin Htar, 2020; Nguyen-Van-Tam, 2022; Shi, 2022; Maggi, 2022; Li,\\n2023], which seem similar to seasonal influenza [Maggi, 2022], and noted a\\nsubstantial case under-ascertainment [Li, 2023]. Moreover, there was a large\\nbetween-country variation in burden estimates [Tin Tin Htar, 2020], which is\\ndriven by numerous factors, from climatic conditions [Haynes, 2013] to case\\ndefinitions and efficiency of the surveillance system in place [Staadegaard,\\n2021]. Notably, the available systematic reviews [Shi, 2020; Tin Tin Htar,\\n2020; Nguyen-Van-Tam, 2022; Shi, 2022; Maggi, 2022; Li, 2023] have identified\\nonly up to six primary studies conducted in Italy. \",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"8o9b8\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"c9t3p\",\"text\":\"Two vaccines have been recently authorized to prevent lower respiratory\\ntract disease (LRTD) caused by RSV in adults aged ≥ 60 years [Kotton, 2023].\\nThis age indication will be likely extended to younger adults in the upcoming\\nyears. In the United States (US), a single dose of RSV vaccine is recommended\\nto adults ≥ 60 years, as a part of shared clinical decision-making between\\npatient and healthcare provider [CDC, 2023]. In the United Kingdom (UK), RSV\\nvaccination is recommended for older adults aged ≥ 75 years, being the most\\ncost-effective option [United Kingdom Department of Health \\u0026 Social Care,\\n2023]. By contrast, as of November 2023, no recommendations have been issued in\\nItaly.\",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"18n1i\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"aaov6\",\"text\":\"Understanding country-specific burden of disease (BoD) is a key driver\\nfor policy decisions on the introduction of new vaccines [Levine, 1997]. A\\nsystematic appraisal of the burden of RSV enables policy makers, health\\nprofessionals and other relevant stakeholders to make informed decisions\\nregarding the recently available vaccines. In this regard, systematic reviews\\non the frequency of different BoD indicators are important in the description\\nof the spatiotemporal distribution and the variation between population\\nsubgroups potentially targeted by the novel preventive measures [Munn 2018;\\nBarker, 2021]. Country-specific BoD indicators are also essential for all types\\nof pharmacoeconomic models.\",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"1fdib\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"5fcod\",\"text\":\"In Italy, a recent systematic review [Boccalini, 2023] has assessed RSV\\nBoD in pediatric outpatients. By including six studies, the authors found that\\n18–41% of children with respiratory infections were positive for RSV.\\nConversely, no review systematically appraised the burden of RSV in Italian\\nadults. Indeed, RSV epidemiology is highly age-dependent, which hinders\\ntransferability of pediatric estimates to other target population groups.\\nFurthermore, as we mentioned earlier, the available global reviews on (older)\\nadults [Shi, 2020; Tin Tin Htar, 2020; Nguyen-Van-Tam, 2022; Shi, 2022; Maggi,\\n2022; Li, 2023] were able to identify only a limited number of Italian studies.\\nIn this systematic review, we aim to comprehensively collect and analyze\\navailable data on the BoD of RSV in Italian adults in both primary care and\\nhospital settings with the ultimate goal of informing and supporting National\\nand local decision makers on the planification and implementation of\\nvaccination strategies.\",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"93u6t\",\"text\":\"\\n\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}}],\"entityMap\":{}}","data":null,"protocol_id":91240,"case_id":0,"critical_ids":"","duration":0,"original_id":0,"number":"1","cases":[],"critical":null},{"id":1855437,"guid":"3CACD4CB18B848C6B734F6FC3A935A48","previous_id":1855436,"previous_guid":"954F72F5583E4884A0A285AC10145C2A","section":"\u003cp\u003eIntroduction\u003c/p\u003e","section_color":"#A492FF","section_duration":0,"is_substep":false,"step":"{\"blocks\":[{\"key\":\"897a\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"ev8b1\",\"text\":\"Methods\",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[{\"style\":\"bold\",\"offset\":0,\"length\":7}],\"entityRanges\":[],\"data\":{}},{\"key\":\"b1lvn\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"afs9l\",\"text\":\" \",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[{\"style\":\"bold\",\"offset\":0,\"length\":1}],\"entityRanges\":[],\"data\":{}},{\"key\":\"bquav\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"fhgb5\",\"text\":\"Reporting\\nstandards\",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[{\"style\":\"bold\",\"offset\":0,\"length\":19}],\"entityRanges\":[],\"data\":{}},{\"key\":\"3ghhs\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"antq4\",\"text\":\" \",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[{\"style\":\"bold\",\"offset\":0,\"length\":1}],\"entityRanges\":[],\"data\":{}},{\"key\":\"4h99n\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"6usp9\",\"text\":\"PRISMA (preferred reporting items for systematic reviews and\\nmeta-analyses) statement [Page, 2021] will be adopted as a reporting standard.\\nMethodological guidance for systematic reviews of observational epidemiological\\nstudies reporting prevalence and cumulative incidence data developed by the\\nJoanna Briggs Institute (JBI) [Zachary, 2015] will be also consulted. \",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"1kt2i\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"1bp26\",\"text\":\" \",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[{\"style\":\"bold\",\"offset\":0,\"length\":1}],\"entityRanges\":[],\"data\":{}},{\"key\":\"2ecmu\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"6v6pc\",\"text\":\"Eligibility\\ncriteria\",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[{\"style\":\"bold\",\"offset\":0,\"length\":20}],\"entityRanges\":[],\"data\":{}},{\"key\":\"7o4rq\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"emjvj\",\"text\":\" \",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"3q29v\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"13ppj\",\"text\":\"All types of observational studies (e.g., surveillance, cross-sectional,\\ncohort, case-series) and published in any modality (i.e., peer-reviewed\\narticle, preprint, conference abstract, official report and other forms of grey\\nliterature) will be eligible. The CoCoPop (condition, context, and population)\\napproach [Munn, 2015] will be used to formulate the inclusion criteria. In\\nparticular, the condition of interest will be RSV infection detected by any\\nlaboratory technique, including reverse-transcription polymerase chain reaction\\n(RT-PCR), cell culture, immunofluorescence assay (IFA) and rapid antigen\\ndetection test (RADT). Moreover, RSV-specific International Statistical Classification\\nof Diseases and Related Health Problems (ICD) diagnosis codes will be also\\nconsidered a good proxy for the true RSV infection. Indeed, specificity of the\\nRSV-specific codes is 99.6–99.8% [Pisesky, 2016; Cai, 2020].\",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"fp5vv\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"dq7iu\",\"text\":\"For the context, we will consider studies conducted in Italy, in any\\nsetting (outpatient, inpatient or mixed) and calendar period. For this latter,\\nit is important to distinguish between year-around studies and those conducted\\nduring a typical RSV season, in which the probability of RSV detection is much\\nhigher [Rozenbaum, 2023]. We will define RSV epidemic season as a period\\nbetween October and April [Hamid, 2023]. \",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"cgg3n\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"258k4\",\"text\":\"Population will consist of adults defined as individuals aged  ≥ 14/18 years. When possible, we will\\nconsider estimates for different age subgroups (e.g., working-age and older\\nadults) reported by single studies. Any clinical entity [e.g., influenza-like\\nillness (ILI), acute respiratory infection (ARI), severe ARI (SARI)] that\\ntriggers swab collection will be eligible.\",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"asds6\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"ctoni\",\"text\":\"The following will be the exclusion criteria: (i) modeling,\\npharmacoeconomic and similar studies with no original data; (ii) records with\\ninsufficient data on RSV; (ii) studies on general population with no separate\\ndata for adults; (iii) multi-country studies with no separate information for\\nItaly; (iv) redundant publications.\",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"ct5rp\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"dju2r\",\"text\":\" \",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[{\"style\":\"bold\",\"offset\":0,\"length\":1}],\"entityRanges\":[],\"data\":{}},{\"key\":\"61bmk\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"lsuv\",\"text\":\"Study\\nendpoints\",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[{\"style\":\"bold\",\"offset\":0,\"length\":15}],\"entityRanges\":[],\"data\":{}},{\"key\":\"df9ot\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"815o0\",\"text\":\" \",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"9lnk7\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"dkuif\",\"text\":\"RSV attack rate (cumulative incidence) will be defined as the occurrence\\nof laboratory-confirmed RSV detections in a population (symptomatic/medically\\nattended, asymptomatic or both) in a specific period (e.g., RSV season). RSV\\nprevalence (overall, by subtype and genotype) will be defined as proportion of\\nRSV detections to the total number of subjects tested. Prevalence of\\nco-detections will be described as number of samples tested positive for both\\nRSV and any other respiratory pathogen to the total number of samples tested\\npositive for RSV. Case complication rate will be defined as proportion of\\nsubjects tested positive for RSV and who developed at least one complication,\\nsuch as pneumonia, exacerbation of chronic obstructive pulmonary disease,\\nasthma, or congestive heart failure. As for drug use indicators, we will consider\\nfrequency of drug prescriptions among subjects who was diagnosed with RSV. For\\nwhat concerns inpatient outcomes, crude hospitalization (per 100,000), case\\nhospitalization (i.e., proportion of RSV-positive individuals who were hospitalized)\\nrates, length of stay, frequency of admission to intensive care units will be\\nof interest. Analogously, crude, in-hospital, 30-day mortality and\\ncase-fatality rates will be eligible. For these indicators, we will consider\\nonly RSV-specific codes for RSV pneumonia (ICD-9-CM: 480.1; ICD-10-CM: J12.1),\\nacute bronchiolitis due to RSV (ICD-9-CM: 466.11; ICD-10-CM: J21.0), acute\\nbronchitis due to RSV (ICD-10-CM: J20.5), and RSV as the cause of diseases\\nclassified elsewhere (ICD-9-CM: 079.6; ICD-10-CM: B97.4).\",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"4rrea\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"bjvo0\",\"text\":\"When possible, all study endpoints will be described overall, by age\\ngroup (working-age and older adults) and RSV season. Additional not\\nprespecified endpoints will be also eligible for exploratory purposes.\",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"d0ld4\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"eonm3\",\"text\":\" \",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[{\"style\":\"bold\",\"offset\":0,\"length\":1}],\"entityRanges\":[],\"data\":{}},{\"key\":\"e0opp\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"fms3d\",\"text\":\"Search\\nstrategy\",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[{\"style\":\"bold\",\"offset\":0,\"length\":15}],\"entityRanges\":[],\"data\":{}},{\"key\":\"d1hln\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"1b0i3\",\"text\":\" \",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"ftf72\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"dst10\",\"text\":\"The automatic search will be performed in the\\nfollowing: PubMed/Medline, Biological Abstracts, Global Health through Ovid and\\nScopus. In order to increase sensitivity, the number of selection criteria will\\nbe minimized to the condition and population of interest and no filters or\\nother restrictions (e.g., language or publication year) will be applied. The\\nsearch following script, which will be adapted to each citation database, will\\nbe used: (“Respiratory Syncytial Viruses”[MeSH Terms] OR \\\"Respiratory\\nSyncytial Virus, Human\\\"[MeSH Terms] OR “Respiratory Syncytial Virus\\nInfections” [MeSH Terms] OR “respiratory syncytial” OR “RSV”) AND (“Adult”\\n[MeSH Terms] OR “Aging”[MeSH Terms] OR “Men”[MeSH Terms] OR “Women”[MeSH Terms]\\nOR “Retirement”[MeSH Terms] OR “Long-term care”[MeSH Terms] OR “Nursing\\ncare”[MeSH Terms] OR “Palliative care”[MeSH Terms] OR pension* OR retire* OR\\nadult* OR aged OR elderly OR senior* OR geriatric* OR nursing home*) AND\\n(“Italy”[MeSH Terms] OR Italy OR Italian*).\",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"9ara5\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"djut1\",\"text\":\"We will then perform a manual search through several\\ntwo modalities. First, the reference lists of the available systematic reviews\\nwill be checked. Second, a backward cross-reference checking of the included\\nstudies will be carried out. Third, a forward citation search by using Google\\nScholar (https://scholar.google.com/) will be performed, as this search engine\\nis better suited for identifying grey literature sources [Haddaway, 2015].\\nFourth, periodic reports of the Italian surveillance reports on influenza and\\nother respiratory viruses (https://respivirnet.iss.it) will be examined.\\nFinally, we will screen abstract books and proceedings of some relevant\\nconferences, including ECCMID (European Society of Clinical Microbiology and\\nInfectious Diseases), ESWI (European Scientific Working Group on Influenza) and\\nReSViNET.\",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"62f4c\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"a332e\",\"text\":\" \",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"btp4s\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"2scqq\",\"text\":\"Study\\nselection\",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[{\"style\":\"bold\",\"offset\":0,\"length\":15}],\"entityRanges\":[],\"data\":{}},{\"key\":\"6kjn3\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"cfac1\",\"text\":\" \",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"6ec7v\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"5iq8h\",\"text\":\"Results of the automatic search will be merged into a\\nsingle spreadsheet and duplicates will be removed in a semi-automatic modality.\\nThe resulting list of unique records will undergo the process of screening by\\nassessing titles and/or abstracts and clearly irrelevant citations will be\\ndiscarded. Full texts of potentially pertinent publications records will be\\nthen downloaded and assessed for the eligibility criteria described earlier.   Selection will be finalized by performing\\nthe manual search, as described above. The entire process of study selection will\\nbe performed by two reviewers, each working independently, and eventual\\ndisagreements will be solved by consensus.\",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"5kjfg\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"eap6f\",\"text\":\" \",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"4pkdt\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"45sur\",\"text\":\"Data\\nextraction and coding\",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[{\"style\":\"bold\",\"offset\":0,\"length\":26}],\"entityRanges\":[],\"data\":{}},{\"key\":\"gglm\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"728qk\",\"text\":\" \",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"5g08a\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"bqk6f\",\"text\":\"The following data will be extracted into a\\nspreadsheet: (i) full citation record; (ii) location (region); (iii) period;\\n(iv) design; (v) setting; (vi) population; (vii) sample size; (viii) funding\\nsource; (ix) definition of the clinical entity that triggered swab collection;\\n(x) methods used for RSV case ascertainment; (xi) numerators and denominators\\nused to compute the endpoints of interest described above. On the basis of\\nperiod, studies will be dichotomized on whether they overlapped with the\\nCOVID-19 pandemic, which had a significant impact on circulation of RSV and\\nmany other respiratory viruses. In particular, the northern hemisphere winter\\nseason 2020/21 was characterized by the absence of very limited circulation of\\nRSV [Hamid, 2023; Boccalini, 2023; Gomez, 2021]. Estimates for that season will\\nbe extracted and reported, but not included in the quantitative synthesis.\\nStarting from the 2021/22 season, RSV returned to the epidemiological scene\\n[Hamid, 2023] and therefore estimates from 2021/22 will be fully considered.\\nMulti-season studies that reported separate seasonal estimates will be\\nconsidered as distinct estimates [Bergeri, 2022]. On the basis of sample size,\\nstudies will be median split. Regions will be categorized into three macro-areas\\nof North (Aosta Valley, Liguria, Lombardy, Piedmont, Emilia-Romagna,\\nFriuli-Venezia Giulia, Trentino-South Tyrol, and Veneto), Center (Lazio,\\nMarche, Tuscany, and Umbria), and South (Abruzzo, Apulia, Basilicata, Calabria,\\nCampania, Molise, Sicily, and Sardinia).\",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"d7dc4\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"4mp1q\",\"text\":\"Missing data on relevant numerators and/or\\ndenominators will be handled as follows. First, the corresponding author will\\nbe contacted by email for clarification. In case of no reply, these data will\\nbe imputed from the available percentages and/or by extracting data from\\nfigures using WebPlotDigitizer v.4.6 (https://automeris.io/WebPlotDigitizer).\\nData will be extracted by AD and then validated by GEC.\",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"6mggn\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"cg6pl\",\"text\":\" \",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"f3mei\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"7a3c2\",\"text\":\"Critical\\nappraisal\",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[{\"style\":\"bold\",\"offset\":0,\"length\":18}],\"entityRanges\":[],\"data\":{}},{\"key\":\"ep7r8\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"f7op6\",\"text\":\" \",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"1td9u\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"bher8\",\"text\":\"The JBI checklist for prevalence/incidence studies\\n[Zachary, 2015] will be used to assess quality of the included studies.\\nCritical appraisal will be performed independently by two reviewers and\\neventual conflicts will be solved by consensus.\",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"6k6th\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"bdv3a\",\"text\":\" \",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"7r4ql\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"a7vq2\",\"text\":\"Data\\nsynthesis\",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[{\"style\":\"bold\",\"offset\":0,\"length\":14}],\"entityRanges\":[],\"data\":{}},{\"key\":\"4mp0b\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"apc7u\",\"text\":\" \",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"1sl9h\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"3b0a7\",\"text\":\"Tabulated data will be first appraised qualitatively and\\nby visualizing forest plots. For quantitative synthesis, a proportional\\nmeta-analysis will be undertaken according to the available recommendations\\n[Zachary, 2015; Barker, 2021]. As heterogeneity is expected to be high, random-effects\\nmodels with double arcsine transformation to stabilize variances will be used.\\nPooled estimates will be expressed as proportions with both 95% Clopper-Pearson\\nexact confidence intervals (CIs) and 95% prediction intervals (PIs).\\nHeterogeneity will be quantified by means of the I2statistic. Notably, high I2 values do not necessarily mean\\nthat data are inconsistent since true heterogeneity is expected in prevalence\\nestimates due to spatiotemporal differences [Barker, 2021]. As recommended,\\npublication bias will be not formally assessed (i.e., by funnel plots or\\nstatistical tests), since there is no consensus about what a positive result in\\na meta-analysis of proportions is [Barker, 2021].\",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[{\"style\":\"italic\",\"offset\":569,\"length\":1},{\"style\":\"italic\",\"offset\":596,\"length\":1},{\"style\":\"sup\",\"offset\":570,\"length\":1},{\"style\":\"sup\",\"offset\":597,\"length\":1}],\"entityRanges\":[],\"data\":{}},{\"key\":\"cqorb\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"db884\",\"text\":\"To investigate the sources of heterogeneity across\\nstudies, both subgroup and meta-regression analyses will be performed. In\\nparticular, the subgroup analysis will be performed by age group (working-age\\nand older adults), setting (outpatient, inpatient and mixed) and study period\\nin relation to the COVID-19 pandemic (before and after the 2020/21 season). The\\nmeta-regression modeling will be then conducted to examine the influence of\\nstudy characteristics on the RSV-related endpoints. This latter will be\\nperformed only when at least 10 estimates are available [The Cochrane\\nCollaboration, 2011].\",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"cpgvf\",\"text\":\"\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"1mbgu\",\"text\":\"Meta-analysis will be performed in R (R Foundation for\\nStatistical Computing; Vienna, Austria) package “Meta” v. 6.5-0.\",\"type\":\"align-justify\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"b57r\",\"text\":\"\\n\\n\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}}],\"entityMap\":{}}","data":null,"protocol_id":91240,"case_id":0,"critical_ids":"","duration":0,"original_id":0,"number":"2","cases":[],"critical":null}],"template_id":1,"title":"Burden of RSV in Italian adults: Protocol for a systematic review and meta-analysis","title_html":"Burden of RSV in Italian adults: Protocol for a systematic review and meta-analysis","type_id":1,"units":[{"id":1,"type_id":3,"name":"µL","can_manage":0,"read_only":0},{"id":2,"type_id":3,"name":"mL","can_manage":0,"read_only":0},{"id":3,"type_id":3,"name":"L","can_manage":0,"read_only":0},{"id":4,"type_id":3,"name":"µg","can_manage":0,"read_only":0},{"id":5,"type_id":3,"name":"mg","can_manage":0,"read_only":0},{"id":6,"type_id":3,"name":"g","can_manage":0,"read_only":0},{"id":7,"type_id":3,"name":"kg","can_manage":0,"read_only":0},{"id":8,"type_id":3,"name":"ng","can_manage":0,"read_only":0},{"id":9,"type_id":3,"name":"Hz","can_manage":0,"read_only":0},{"id":10,"type_id":24,"name":"°C","can_manage":0,"read_only":0},{"id":11,"type_id":24,"name":"°К","can_manage":0,"read_only":0},{"id":12,"type_id":24,"name":"°F","can_manage":0,"read_only":0},{"id":13,"type_id":25,"name":"Mass Percent","can_manage":0,"read_only":0},{"id":14,"type_id":25,"name":"% volume","can_manage":0,"read_only":0},{"id":15,"type_id":25,"name":"Mass / % volume","can_manage":0,"read_only":0},{"id":16,"type_id":25,"name":"Parts per Million (PPM)","can_manage":0,"read_only":0},{"id":17,"type_id":25,"name":"Parts per Billion (PPB)","can_manage":0,"read_only":0},{"id":18,"type_id":25,"name":"Parts per Trillion (PPT)","can_manage":0,"read_only":0},{"id":19,"type_id":25,"name":"Mole Fraction","can_manage":0,"read_only":0},{"id":20,"type_id":25,"name":"Mole Percent","can_manage":0,"read_only":0},{"id":21,"type_id":25,"name":"Molarity (M)","can_manage":0,"read_only":1},{"id":22,"type_id":25,"name":"Molarity (m)","can_manage":0,"read_only":0},{"id":23,"type_id":25,"name":"Genome copies per ml","can_manage":0,"read_only":0},{"id":24,"type_id":3,"name":"μV","can_manage":0,"read_only":0},{"id":25,"type_id":3,"name":"ms","can_manage":0,"read_only":0},{"id":26,"type_id":3,"name":"pg","can_manage":0,"read_only":0},{"id":27,"type_id":25,"name":"Molarity dilutions","can_manage":0,"read_only":0},{"id":28,"type_id":25,"name":"millimolar (mM)","can_manage":0,"read_only":0},{"id":29,"type_id":25,"name":"micromolar (µM)","can_manage":0,"read_only":0},{"id":30,"type_id":25,"name":"nanomolar (nM)","can_manage":0,"read_only":0},{"id":31,"type_id":25,"name":"picomolar (pM)","can_manage":0,"read_only":0},{"id":32,"type_id":24,"name":"Room temperature","can_manage":0,"read_only":0},{"id":33,"type_id":30,"name":"rpm","can_manage":0,"read_only":0},{"id":34,"type_id":30,"name":"x g","can_manage":0,"read_only":0},{"id":165,"type_id":24,"name":"On ice","can_manage":0,"read_only":0},{"id":200,"type_id":32,"name":"cm","can_manage":0,"read_only":0},{"id":201,"type_id":32,"name":"mm","can_manage":0,"read_only":0},{"id":202,"type_id":32,"name":"µm","can_manage":0,"read_only":0},{"id":203,"type_id":32,"name":"nm","can_manage":0,"read_only":0},{"id":204,"type_id":25,"name":"mg/mL","can_manage":0,"read_only":0},{"id":205,"type_id":25,"name":"µg/µL","can_manage":0,"read_only":0},{"id":206,"type_id":25,"name":"% (v/v)","can_manage":0,"read_only":0},{"id":207,"type_id":3,"name":"V","can_manage":0,"read_only":0},{"id":1324,"type_id":30,"name":"rcf","can_manage":0,"read_only":0},{"id":1359,"type_id":35,"name":"Bar","can_manage":0,"read_only":0},{"id":1360,"type_id":35,"name":"Pa","can_manage":0,"read_only":0}],"uri":"burden-of-rsv-in-italian-adults-protocol-for-a-sys-c5cgy2tw","url":"https://www.protocols.io/view/burden-of-rsv-in-italian-adults-protocol-for-a-sys-c5cgy2tw","version_class":91240,"version_data":{"id":0,"code":"c5cgy2tw","version_class":91240,"parent_id":null,"parent_uri":null,"is_same_owner":false,"is_parent_public":false,"has_pending_merge_request":false,"has_approved_merge_request":false,"merge_request":null},"version_id":0,"version_uri":"burden-of-rsv-in-italian-adults-protocol-for-a-sys-5qpvo32odv4o/v1","versions":[{"id":91240,"title":"Burden of RSV in Italian adults: Protocol for a systematic review and meta-analysis","title_html":"Burden of RSV in Italian adults: Protocol for a systematic review and meta-analysis","image":{"source":"https://www.protocols.io/img/default_protocol.png","webp_source":null,"placeholder":"https://www.protocols.io/img/default_protocol.png","webp_placeholder":null},"doi":"dx.doi.org/10.17504/protocols.io.5qpvo32odv4o/v1","uri":"burden-of-rsv-in-italian-adults-protocol-for-a-sys-c5cgy2tw","published_on":1700562406,"modified_on":1700562406,"version_class":91240,"version_id":0,"version_code":"c5cgy2tw","version_uri":"burden-of-rsv-in-italian-adults-protocol-for-a-sys-5qpvo32odv4o/v1","created_on":1700555782,"categories":null,"type_id":1,"creator":{"name":"Alexander Domnich","affiliation":"IRCCS Ospedale Policlinico San Martino","affiliation_url":"","username":"alexander-domnich","link":"","image":{"source":"/img/avatars/011.png","placeholder":"/img/avatars/011.png","webp_source":""}},"stats":{"number_of_comments":0,"last_comment_time":0}}],"warning":""}